Our Commercial team is responsible for all the Association’s work on the Value & Access imperatives and all commercial issues, i.e. all aspects of a medicine's life from the granting of a licence/marketing authorisation onwards.
Today sees the launch of a new ABPI quick start reference guide on Joint Working which has been developed in response to feedback gathered from our members and NHS partners. Read more
Today we published our response to the GMC consultation on 'Good practice in prescribing and managing medicines and devices'.Read more
We are delighted to announce our second one day ABPI Masterclass on PPRS, taking place on 10 June at the Royal Society, SW1.
We are delighted to announce our first one day ABPI Masterclass on PPRS, taking place on 16 May at the Royal Society, SW1. Read more
Today’s front page story in the Daily Telegraph “Patients are denied high cost drugs by NHS trusts” raises new concerns about an on-going problem – how to improve patient access to new innovative medicines in the NHS.Read more
Value based pricing will be introduced into the UK from January 2014 and is expected to be one of the biggest reforms to the pricing of new medicines in the UK since the Pharmaceutical Price Regulation Scheme was set up more than 50 years ago. Read more
7th floor, Southside, 105 Victoria Street, London, SW1E 6QT Telephone +44 (0) 870 890 4333
ABPI Cymru Wales
ABPI Northern Ireland
The Prescription Medicines Code of Practice Authority (PMCPA) is responsible for administering the ABPI Code of Practice for the Pharmaceutical Industry at arm's length of the ABPI itself.
The Office of Health Economics (OHE) provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.